Published by Josh White on 17th January 2023
(Sharecast News) - Oncology drug and diagnostics developer Avacta Group said in an update on Tuesday that 'AVA6000' was continuing to show a "very favourable" safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase-one clinical trial.
URL: http://www.digitallook.com/dl/news/story/33241554/...